Press Releases

 
Press Releases
  Date Summary View
Jan 25, 2016
Five Patents for PROCYSBI Now Listed in FDA Orange Book Orphan Drug Exclusivity Extended in Nephropathic Cystinosis Patients 2-6 Years Old NOVATO, Calif., Jan. 25, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that a U.S. PROCYSBI paten...
Dec 10, 2015
NOVATO, Calif., Dec. 10, 2015 /PRNewswire/ -- Raptor Pharmaceutical Corp. (Nasdaq: RPTP) today announced 36-month efficacy results from a Phase 2/3 clinical trial evaluating RP103 for the potential treatment of Huntington's disease, called CYST-HD, conducted in collaboration with the Centre Hospitalier Universitaire d'Angers (CHU d'Angers), France....
Nov 16, 2015
NOVATO, Calif., Nov. 16, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (NASDAQ:RPTP) today announced researchers have provided additional results from the CyNCh study of RP103 for the treatment of children 8 to 17 years with biopsy-confirmed moderate-to-severe nonalcoholic fatty liver disease, or NAFLD. The data will be presented tod...
Nov 5, 2015
Record PROCYSBI® Product Sales of $25.8 Million Raptor Raises 2015 PROCYSBI Revenue Guidance to $90-$95 Million Company to Host Conference Call and Webcast Today at 4:30 p.m. EST NOVATO, Calif., Nov. 5, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (NASDAQ:RPTP), a biopharmaceutical company developing and commercializing tra...
Oct 29, 2015
NOVATO, Calif., Oct. 29, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the company will release third quarter 2015 financial results on Thursday, November 5, 2015, after market close. Management will conduct a conference call and live audio webcast at 4:30 p.m. ET (1:30 p.m. PT) that day to discuss the fina...
Oct 5, 2015
NOVATO, Calif., Oct. 5, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it has completed the acquisition of Quinsair™ (levofloxacin inhalation solution) from Tripex Pharmaceuticals. Quinsair is the first inhaled fluoroquinolone antibiotic approved in the European Union and in Canada for the management o...
Sep 23, 2015
NOVATO, Calif., Sept. 23, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it will participate in the following investor conference: Julie Anne Smith, President and Chief Executive Officer, will participate in the Leerink Partners 4th Annual Rare Disease Roundtable being held Wednesday, September...
Sep 14, 2015
NOVATO, Calif., Sept. 14, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced topline results from the Phase 2b CyNCh study, which did not meet its primary endpoint of improving nonalcoholic steatohepatitis (NASH) in children. The trial evaluated the safety and efficacy of RP103, or cysteamine bitartrate delay...
Aug 20, 2015
NOVATO, Calif., Aug. 20, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) announced today that it was named among the top workplaces in the North Bay in the 10th Annual North Bay Business Journal competition. The results of the best places to work in the North Bay, will be featured in the September 28, 2015 publication of the Nort...
Aug 20, 2015
First Inhaled Fluoroquinolone Therapy for Patients with Cystic Fibrosis Approval Received in the European Union and CanadaExpansion of Pipeline with Multiple Late-Stage Orphan Indication Opportunities Raptor to Host Conference Call and Webcast Today at 5:30 p.m. EDT/2:30 p.m. PDT NOVATO, Calif., Aug. 20, 2015 (GLOBE NEWSWIRE) -- Raptor Phar...
Page:
1
... NextLast
= add release to Briefcase